Articles tagged "HLA antibodies"

2020 American Transplant Congress
The Association between Alloimmunity and De Novo Glomerulonephritis Post Kidney Transplantation
P. Khairallah, J. Kamal, E. Vasilescu, I. Batal, G. Dube
Columbia University Medical Center, New York, NY
*Purpose: In contrast to recurrent immune complex-mediated glomerulonephritis (ICGN), de novo ICGN of the allograft is poorly characterized. We hypothesize that alloimmunity results in immune-complex…
2020 American Transplant Congress
Clinical Significance of T Cell and B Cell Epitope Prediction as a Risk Factor of De Novo DSA Production after Kidney Transplantation
T. Kobayashi¹, K. Iwasaki¹, T. Tomosugi², Y. Miwa¹, M. Niemann³, E. Spierings⁴, K. Horimi¹, Y. Matsuoka¹, A. Takeda², N. Goto², S. Narumi², Y. Watarai²
¹Aichi Medical University School of Medicine, Nagakute, Japan, ²Nagoya Daini Red Cross Hospital, Nagoya, Japan, ³PIRCHE AG, Berlin, Germany, ⁴UMC Utrecht, Utrecht, Netherlands
*Purpose: Chronic antibody-mediated rejection caused by de novo DSA (dnDSA) is a major cause of graft failure. Risk prediction of dnDSA would be important for…
2020 American Transplant Congress
A Multicenter Analysis of the Proportion and Pattern of Unexplained HLA Antibodies in Kidney Recipients without a History of Sensitization
J. Lan¹, J. S. Gill¹, H. M. Gebel², R. A. Bray², R. Liwski³, A. Vinson⁴, A. Greenshields³, S. Dobrer⁵, O. Gunther⁵, K. Sherwood⁵, F. H. Claas⁶, S. Heidt⁶, G. Karahan⁶, J. Gill⁷, M. Gill¹, U. Varyani¹, P. Jindal¹, P. Keown⁵
¹Medicine, Division of Nephrology, University of British Columbia, Vancouver, BC, Canada, ²Pathology, Emory University, Atlanta, GA, ³Pathology, Dalhousie University, Halifax, NS, Canada, ⁴Nephrology, Dalhousie University, Halifax, NS, Canada, ⁵Pathology, University of British Columbia, Vancouver, BC, Canada, ⁶Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands, ⁷Nephrology, Emory University, Atlanta, GA
*Purpose: Previous studies report a high prevalence of unexplained antibody reactivities on the single antigen bead (SAB) test. In a contemporary multicenter cohort of non-sensitized…
2020 American Transplant Congress
Donor-Specific Antibody Test as a Screening Tool for Stable Long-Term Kidney Transplant Recipients
M. Mohamed¹, L. Hidalgo², S. Parajuli¹, N. Garg¹, F. Aziz¹, K. Swanson¹, E. Jochaim¹, D. Mandelbrot¹, A. Djamali¹, B. Astor¹
¹Department of Nephrology, Madison, WI, ²Department of Surgery, Madison, WI
*Purpose: Donor-specific antibody (DSA) is an established biomarker predicting antibody mediated rejection (AMR), but at substantial cost. The utility of DSA test as a screening…
2020 American Transplant Congress
Crosstalk between TLR4 and HLA Class I Mediates P-Selectin Expression and Monocyte Capture to Endothelial Cells
Y. Jin, N. M. Valenzuela, R. A. Sosa, E. F. Reed
Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
*Purpose: Transplant recipients developing donor specific HLA antibodies (DSA) are at risk for acute and chronic antibody-mediated rejection (AMR). DSA contribute to the process of…
2020 American Transplant Congress
Effects of Donor Specific Antibodies in Intestinal/Multivisceral Transplant Recipients
K. Klein¹, M. Keck², E. Langewisch², S. Merani², M. Leick²
¹University Health System, San Antonio, TX, ²Nebraska Medicine, Omaha, NE
*Purpose: Evaluate the effects of donor specific antibodies (DSAs) on outcomes in post-intestinal/multivisceral (MV) transplant patients and describe the presentation of DSAs post-transplant.*Methods: This single-center…
2020 American Transplant Congress
Is the Epitope Mismatch Load Enough to Identify HLA-DQ Mismatches with a Low Risk for De Novo DSA Development?
V. Jucaud¹, M. Stegall², C. Schinstock², R. Heilman³, L. Rebellato⁴, M. Samaniego-Picota⁵, D. Leeser⁴, M. Gandhi², J. Beaumont¹, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Phoenix, AZ, ⁴East Carolina University, Greenville, NC, ⁵Henry Ford Transplant Institute, Detroit, MI
*Purpose: The development of de novo donor-specific anti-HLA antibodies (dnDSA) remains a major risk factor for poor long-term kidney allograft outcomes. In particular, anti-HLA-DQ dnDSAs,…
2020 American Transplant Congress
Association between Longer Hospitalization and Development of De Novo Donor Specific Antibody in Simultaneous Liver-Kidney Transplant Recipients
M. Yazawa¹, O. Cseprekal², R. A. Helmick¹, M. Talwar¹, V. Balaraman¹, P. S. Podila³, S. Fossey⁴, S. K. Satapathy⁵, J. D. Eason¹, M. Z. Molnar¹
¹James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN, ²Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary, ³Faith & Health Division, Methodist Le Bonheur Healthcare, Memphis, TN, ⁴Transplant Immunology Laboratory, DCI Inc., Nashville, TN, ⁵Sandra Atlas Bass Center for Liver Diseases & Transplantation, Northshore University Hospital/Northwell Health, Manhasset, NY
*Purpose: De novo Donor Specific Antibodies (DSA) are considered a risk factor for worsening kidney allograft outcomes in recipients after simultaneous liver-kidney transplantation (SLK). No…
2019 American Transplant Congress
De Novo Donor Specific Antibody and Panel Reactivity Antibody Are Critical Risk Factors for Antibody Mediated Rejection of Kidney Allograft after Simultaneous Liver-Kidney Transplantation (a Single Center Study Using Surveillance Renal Biopsies)
Y. Sun¹, A. Zhang², Z. Zaky²
¹Avalon Medical University, Willemstad, Netherlands Antilles, ²Cleveland Clinic, Cleveland, OH
*Purpose: Even though the liver may provide immunologic protection to the kidney from hyperacute rejection, previous publications suggest this protective effect is not sufficient to…
2019 American Transplant Congress
ABO Incompatibility in Kidney Transplantation Can Increase a Safety Margin of Epitope Mismatch Levels against De Novo DSA Production
T. Kobayashi¹, K. Iwasaki¹, M. Okada², K. Horimi¹, Y. Matsuoka¹, A. Takeda², N. Goto², S. Narumi², Y. Watarai²
¹Aichi Medical University School of Medicine, Nagakute, Japan, ²Nagoya Daini Red Cross Hospital, Nagoya, Japan
*Purpose: Chronic antibody-mediated rejection (cABMR) caused by de novo donor specific HLA antibodies (DSA) is one of major obstacles to long term graft outcome. ABO…